Parallel Bio

Parallel Bio, based in Cambridge, MA, is pioneering the use of immune organoids and artificial intelligence to develop innovative immunotherapies that are safe and effective for human patients from the outset. By creating in-vitro replicas of human lymph nodes, the company aims to replace traditional animal models in drug discovery, significantly reducing development time and costs.

The company's mission is to revolutionize the pharmaceutical industry by providing a more ethical and efficient approach to drug development, enabling faster access to therapies for a diverse range of diseases. With a focus on harnessing the immune system's capabilities, Parallel Bio is positioned to transform the future of medicine and improve health outcomes globally.

Generated from the website